Key result
Rivaroxaban linked to ~31% lower recurrent VTE risk vs. LMWH in active cancer.
Why the study?
DOACs are alternatives to LMWH in most cancer-associated thrombosis patients, but comparative effectiveness and safety data were needed in patients with active cancer types not associated with high DOAC bleeding risk.
Does rivaroxaban reduce recurrent VTE or impact bleeding and mortality compared to LMWH in patients with active cancer who are not at high risk of DOAC bleeding?
Cohort (n=3,708)
Yes
Does rivaroxaban reduce recurrent VTE or impact bleeding and mortality compared to LMWH in patients with active cancer who are not at high risk of DOAC bleeding?
In patients with cancer-associated thrombosis not at high risk for DOAC bleeding, rivaroxaban reduces recurrent VTE at 3 and 6 months without increasing clinically relevant bleeding compared to LMWH.
Rivaroxaban was associated with lower 3-month recurrent VTE risk in low-bleeding-risk cancer patients; leaves open practice change without randomized confirmation.
Background: Direct-acting oral anticoagulants (DOACs) are alternatives to low molecular weight heparin (LMWH) in most cancer-associated thrombosis (CAT) patients. Objectives: This study sought to compare the effectiveness and safety of rivaroxaban and LMWH for venous thromboembolism (VTE) treatment in patients with an active cancer type not associated with a high risk of DOAC bleeding. Methods: An analysis of electronic health records from January 2012 to December 2020 was performed. Patients were adults, had active cancer, experienced an index CAT event, and were treated with rivaroxaban or LMWH. Patients with cancers with an established high risk of bleeding on DOACs were excluded. Baseline covariates were balanced using propensity score-overlap weighting. HRs with 95% CIs were calculated. Results: We identified 3,708 CAT patients treated with rivaroxaban (29.5%) or LMWH (70.5%). The median (25th-75th percentiles) time on anticoagulation was 180 (69-365) and 96 (40-336) days for rivaroxaban and LMWH patients. At 3 months, rivaroxaban was associated with a 31% reduced risk of recurrent VTE vs LMWH (4.2% vs 6.1%; HR: 0.69; 95% CI: 0.51-0.92). No difference in bleeding-related hospitalizations or all-cause mortality was observed (HR: 0.79; 95% CI: 0.55-1.13 and HR: 1.07; 95% CI: 0.85-1.35, respectively). Rivaroxaban reduced the recurrent VTE risk (HR: 0.74; 95% CI: 0.57-0.97) but not bleeding-related hospitalizations or all-cause mortality at 6 months. At 12 months, no difference was observed between cohorts for any of the previously mentioned outcomes. Conclusions: Among active cancer patients experiencing VTE and not at high risk of bleeding on DOACs, rivaroxaban was associated with a reduced risk of recurrent VTE versus LMWHs at 3 and 6 months but not 12 months. (Observational Study in Cancer-Associated Thrombosis for Rivaroxaban-United States Cohort [OSCAR-US]; NCT04979780).
No takes yet. Share an insight, caveat, or question.
Coleman et al. (2023) conducted a cohort in Cancer-Associated Venous Thromboembolism (n=3,708). Rivaroxaban vs. Low molecular weight heparin (LMWH) was evaluated on Recurrent VTE at 3 months (HR 0.69, 95% CI 0.51-0.92). Rivaroxaban reduced the risk of recurrent VTE by 31% at 3 months compared to LMWH (HR 0.69, 95% CI 0.51-0.92) in active cancer patients without a high risk for DOAC-related bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: